Trial Information

Follow-Up Observational Study In CHAT Trial Participants With Advanced And/Or Metastatic Breast Cancers That Overexpress HER2, Who Were Randomised To Receive Trastuzumab And Docetaxel With Or Without Capecitabine

The objective of this study is to gain mature data on the long-term efficacy of the
combination of Trastuzumab and Docetaxel with or without capecitabine as first-line therapy
for HER2 positive locally advanced or metastatic breast cancer.

The study also aims to gain information on the additional treatments and sequencing used in
patients that have progressed following the combination of Trastuzumab and Docetaxel with or
without capecitabine as first-line therapy for HER2 positive locally advanced or metastatic
breast cancer.

Overall Survival data on patients who have progressed following the combination of
Trastuzumab and Docetaxel with or without capecitabine as first-line therapy for HER2
positive locally advanced or metastatic breast cancer will also be analysed and reported.